Literature DB >> 18383566

Lipopolysaccharide-induced monocyte chemotactic protein-1 is enhanced by suppression of nitric oxide production, which depends on poor CD14 expression on the surface of skeletal muscle.

Noriaki Kawanishi1, Yohei Tanaka, Yasuko Kato, Daisuke Shiva, Hiromi Yano.   

Abstract

It is known that lipopolysaccharide (LPS)-induced monocyte chemotactic protein (MCP)-1 secretion from tissues recruits monocytes from the circulation, but the mechanism of the LPS-induced MCP-1 production in skeletal muscle is largely unexplained. To clarify the effect of LPS on MCP-1 production in skeletal muscle cells, C2C12 cells from a mouse skeletal muscle cell line, and RAW 264.7 cells from a mouse macrophage cell line, were used to assess production of LPS-induced MCP-1, nitric oxide (NO) and interferon (IFN)-beta. In addition, we evaluated inducible NO synthases (iNOS) mRNA expression using RT-PCR, and cell surface expression of CD14 and toll-like receptor (TLR) 4 using flow cytometry. In C2C12 cells, LPS stimulation increased MCP-1 production (p < 0.01), but combined treatment with LPS and NO inducer, diethylammonium (Z)-1-(N,N-diethylamino) diazen-1-ium-1,2-diolate (NONOate), significantly inhibited its production (p < 0.01). LPS stimulation neither induced production of NO nor of IFN-beta, which is an NO inducer. Recombinant IFN-beta stimulation, on the other hand, enhanced LPS-induced NO production (p < 0.01). Interestingly, we found that surface expression of CD14, which regulates IFN-beta production, in C2C12 cells was much lower than that in RAW 264.7 cells, although TLR4 expression on C2C12 cells was similar to that on RAW 264.7 cells. These data suggest that the reduced NO production in response to LPS may depend on low expression of CD14 on the cell surface of skeletal muscle, and that it may enhance LPS-induced MCP-1 production. Together, these functions of skeletal muscle could decrease the risk of bacterial infection by recruitment of monocytes. (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18383566     DOI: 10.1002/cbf.1471

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  6 in total

1.  Lipopolysaccharide-Induced Cytokine Secretion from In Vitro Mouse Slow and Fast Limb Muscle.

Authors:  Alex J Mattingly; Orlando Laitano; Christian K Garcia; Gerard P Robinson; Thomas L Clanton
Journal:  Shock       Date:  2022-04-01       Impact factor: 3.454

2.  Effect of Lianshu preparation on lipopolysaccharide-induced diarrhea in rats.

Authors:  Jun Liu; Rong Wan; Xuan-Fu Xu; Xing-Peng Wang; Wen-Juan Yang; Yu-Jing Xia; Hua Liu; Qian-Lin Yan; De-Xin Yan; Chuan-Yong Guo
Journal:  World J Gastroenterol       Date:  2009-04-28       Impact factor: 5.742

3.  NLRP3 inflammasome up-regulates major histocompatibility complex class I expression and promotes inflammatory infiltration in polymyositis.

Authors:  Ping Xia; Yu-Quan Shao; Cong-Cong Yu; Yu Xie; Zhi-Jie Zhou
Journal:  BMC Immunol       Date:  2022-08-14       Impact factor: 3.594

4.  Inhibition of Lipopolysaccharide-Induced Inflammatory and Oxidative Responses by Trans-cinnamaldehyde in C2C12 Myoblasts.

Authors:  Cheol Park; Hyesook Lee; Suhyun Hong; Ilandarage Menu Neelaka Molagoda; Jin-Woo Jeong; Cheng-Yun Jin; Gi-Young Kim; Sung Hyun Choi; Sang Hoon Hong; Yung Hyun Choi
Journal:  Int J Med Sci       Date:  2021-04-23       Impact factor: 3.738

5.  Lipopolysaccharide Disrupts Mitochondrial Physiology in Skeletal Muscle via Disparate Effects on Sphingolipid Metabolism.

Authors:  Melissa E Hansen; Kurtis J Simmons; Trevor S Tippetts; Mikayla O Thatcher; Rex R Saito; Sheryl T Hubbard; Annie M Trumbull; Brian A Parker; Oliver J Taylor; Benjamin T Bikman
Journal:  Shock       Date:  2015-12       Impact factor: 3.454

6.  TLR4-defective (C3H/HeJ) mice are not protected from cast immobilization-induced muscle atrophy.

Authors:  Noriaki Kawanishi; Risa Nozaki; Hisashi Naito; Shuichi Machida
Journal:  Physiol Rep       Date:  2017-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.